GLP-1R agonists, unlike endogenous intestinal GLP-1, are stable and have a longer half-life in the circulation and hence, act directly on pancreatic β cells (4) and hypothalamic neurons regulating glycemia and/or feeding (5, 6), thereby ameliorating hyperglycemia and overeating through direct action of GLP-1R agonists on target organs such as pancreatic β cells and central nerves (7, 8). The gene discussed is GLP1R; the disease is Hyperglycemia.